Milestone Pharmaceuticals Inc.

NasdaqGS:MIST 주식 보고서

시가총액: US$87.3m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Milestone Pharmaceuticals 미래 성장

Future 기준 확인 2/6

Milestone Pharmaceuticals은 연간 수입과 매출이 각각 50.8%와 66.4% 증가할 것으로 예상되고 EPS는 연간 52.6%만큼 증가할 것으로 예상됩니다.

주요 정보

50.8%

수익 성장률

52.6%

EPS 성장률

Pharmaceuticals 수익 성장27.3%
매출 성장률66.4%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트20 Jun 2024

최근 미래 성장 업데이트

Recent updates

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

Sep 13
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Mar 07
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Oct 15
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02
Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15
What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

수익 및 매출 성장 예측

NasdaqGS:MIST - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202630-35-30-142
12/31/20254-72-49-384
12/31/2024N/A-43-30-264
3/31/2024N/A-55-42-41N/A
12/31/20231-60-47-46N/A
9/30/20235-59-50-49N/A
6/30/20236-59-49-49N/A
3/31/20236-59-53-52N/A
12/31/20225-58-53-52N/A
9/30/20222-62-52-52N/A
6/30/2022N/A-62-50-50N/A
3/31/202215-44-35-35N/A
12/31/202115-43-33-33N/A
9/30/202115-35-30-30N/A
6/30/202115-32-28-28N/A
3/31/2021N/A-46-45-45N/A
12/31/2020N/A-50-51-51N/A
9/30/2020N/A-60-59-59N/A
6/30/2020N/A-60-60-60N/A
3/31/2020N/A-61-55-54N/A
12/31/2019N/A-55-52-51N/A
9/30/2019N/A-47-42-42N/A
6/30/2019N/A-40-39-39N/A
3/31/2019N/A-29-31-31N/A
12/31/2018N/A-23-21-21N/A

애널리스트 미래 성장 예측

수입 대 저축률: MIST 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MIST 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MIST 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MIST 의 수익(연간 66.4% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: MIST 의 수익(연간 66.4% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: MIST 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견